<DOC>
	<DOCNO>NCT00157300</DOCNO>
	<brief_summary>Randomized , double blind , placebo control , prospective trial investigate effect erythropoietin renal transplantation . The investigator postulate erythropoietin reduces risk delay graft function .</brief_summary>
	<brief_title>PROTECT : Prospective Trial Erythropoietin Clinical Transplantation</brief_title>
	<detailed_description>Randomized , double blind , placebo control , prospective trial patient , receive kidney transplantation . Patients randomize receive either Epoetin Beta ( Neorecormon ; Roche ) placebo . The primary endpoint delay graft function . The anticipated duration trial 2 year target sample size 60 patient per arm .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patient Receiving kidney nonheartbeating donor category 3 Donor related factor : prolong warm ischaemic time ( &gt; 45 min ) ; cold ischaemic time &gt; 24 hour ; serum creatinin &gt; 150 umol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>erythropoietin</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>delay graft function</keyword>
</DOC>